Last reviewed · How we verify
AMLODIPINE BENZOATE
Amlodipine Benzoate is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and long-term revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | AMLODIPINE BENZOATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2019 |
Approved indications
Common side effects
Key clinical trials
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMLODIPINE BENZOATE CI brief — competitive landscape report
- AMLODIPINE BENZOATE updates RSS · CI watch RSS